relatlimab is the first lag-3 product to prove itself in PHIII, OK, whether it gets the go ahead from the FDA
in March remains to be seen but appears highly likely......
By then EFTI will be a considerable way into it's Head and Neck cancer in combination with keytruda trial which
immutep applied for and was granted FDA fast track trial status a few months back.....
Given minimal side effect issues and heavy unmet need for H& N Cancer treatment things may work out favourably
for EFTI with possibly a flow on effect for NSCLC...Gonna get very interesting and it's not that far away..
- Forums
- ASX - By Stock
- Overnight Market report
relatlimab is the first lag-3 product to prove itself in PHIII,...
-
- There are more pages in this discussion • 2,716 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 307462 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 118494 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 257462 | 0.285 |
18 | 712543 | 0.280 |
6 | 125918 | 0.275 |
11 | 273188 | 0.270 |
7 | 124774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 118494 | 4 |
0.300 | 623600 | 3 |
0.305 | 191186 | 8 |
0.310 | 507281 | 6 |
0.315 | 138917 | 6 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online